c. NIH policies governing genome-wide association studies (GWAS)
d. Data sharing policies of the National Science Foundation (NSF)
e. Data sharing policies of government agencies-other than NIH or NSF (e.g., Department of Defense, USDA)
f. Policies of private funding organizations and foundations (e.g., HHMI, Wellcome Trust) 
I N F LU E N CE OF OTH E R P OLI CI ES (P U BLICA TI ON P OLICI E S, TRAI NIN G AN D IN FORM A L P OLICI ES, I N TELLECTU AL P ROP ERTY P OLI CI ES )
c. Policies governing material transfer agreements (MTAs) at your institution
d. Technology transfer policies, other than MTAs, at your institution
e. Agreements with industrial sponsors
f. Your commercial activities (i.e., patenting, licensing, etc.)
g. Publication policies of professional journals
h. Informal rules/norms of your research field 
COM P LI AN CE W I TH J OU RN A L P OLI CI ES
b. Make data available as online supplement
c. Submit biomaterials (e.g., tissues, reagents, organisms, etc.) to third party repository
d. Submit data to third party repository (e.g., GenBank)
e. Transfer biomaterials (e.g., tissues, reagents, organisms, etc.) to accommodate request from another lab
f. Make data available to accommodate request from another lab 
EF F ECT OF JOU RN A L RE QU I REM EN TS ON P ROG RE SS OF RES
c. Third party biomaterials repositories
REV I EW OF DA TA SH A RING P LAN S I N G RAN T P ROPOS A LS

5.
In the last 3 years, have you served as a reviewer of grant proposals for federal agencies that dealt with life science research grants (e.g., NIH, NSF, Department of Defense, Department of Energy)?
No → Go to question <6>.
6.
How influential was the quality of the data sharing plans in your overall evaluation of the proposals you reviewed?
Not at all important
COM P LI AN CE W I TH M A TERI A L TRAN SFER AG REEM EN TS
7.
In the last 3 years, how often have you shared data or materials with someone outside your institution without a material transfer agreement (MTA), even though you knew such an agreement was required by your institution?
Not applicable  6 I am not aware of policies at my institution requiring an MTA.
8.
In those instances when you did not get an MTA from your institution, please indicate the importance of the following factors (asked only of those who answered 2, 3, or 4 to question <7>)
Very important
Moderately important
Not very important
Not at all important a. Scope of MTA overly broad
b. MTA takes too much time to arrange
c. MTA requires too much red tape at own institution
d. MTA negotiations between own and other institution too onerous
e. Philosophically opposed to MTA restrictions
D A TA S HA RIN G IN G ENETI CS
9.
In the last 3 years, has your lab conducted or collaborated on a project that generated primary data for a genome wide association study (GWAS)?
No → Go to question <10>.
10.
In your most recently completed GWAS, were you required to deposit data generated from the study into a data repository (e.g., dbGaP)?
No → Go to question <11>.
11.
In your most recently completed GWAS, did you deposit the required data into the data repository?
No → Go to question <12>.
12.
Please indicate the amount of time that elapsed between the date that data from your most recently completed GWAS was submitted to the repository and the date you submitted your first publication using that data. 
